Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation

Chardan Capital maintained a Buy rating on Intellia Therapeutics (NTLA), with an average one-year price target of $33.78, indicating a 254.79% upside from its $9.52 closing price, supported by projected annual revenue growth of 119.86% to $126 million. While the number of institutional owners slightly decreased, the average portfolio weight dedicated to NTLA increased by 34.92%, and a bullish put/call ratio of 0.41 reflects positive sentiment, with significant stakes held by firms like ARK Investment Management.

Analysis

Chardan Capital maintained a Buy rating for Intellia Therapeutics (NTLA) on November 7, 2025, with an average one-year price target of $33.78, representing a significant 254.79% upside from its $9.52 closing price. This optimistic forecast is underpinned by a projected 119.86% annual revenue growth to $126 million, despite an anticipated non-GAAP EPS of -$6.24.

Institutional sentiment shows a bullish bias, indicated by a low put/call ratio of 0.41. Although the number of institutional owners decreased by 5.87% and total institutional shares declined by 5.05% in the last quarter, the average portfolio weight dedicated to NTLA by reporting funds increased notably by 34.92%. This suggests a higher conviction level among the remaining or new institutional investors.

Key institutional holders exhibit mixed positioning: ARK Investment Management and ARKK ETF increased their share counts but decreased their portfolio allocation to NTLA. In contrast, VTSMX and ARKG both increased their shareholdings and significantly boosted their portfolio allocations by 21.62% and 24.78% respectively. This divergence highlights varied strategic approaches among large investors regarding NTLA's future prospects.

Key Decisions for Investors

• Investors should evaluate NTLA's substantial projected revenue growth and analyst price target upside against the backdrop of continued negative EPS, indicating ongoing investment phase for the biotech firm.
• Monitor institutional ownership dynamics closely, noting the increase in average portfolio weight despite a decrease in total institutional shares and owners, which suggests concentrated conviction among a subset of investors.
• Consider the mixed signals from major institutional holders, where some are increasing share counts but decreasing portfolio allocation, while others are actively increasing both, suggesting a need for deeper due diligence into individual fund strategies.